Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Treatments: Chlorpheniramine

Criteria

Inclusion Criteria:

• 18~65 years old.

• Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.

• Subject can fully understand and voluntarily sign informed consent forms.

Exclusion Criteria:

• Subject with a history of allergic diseases.

• Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.

• Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.

• Subject transfused with washed RBC.

• Received allo-HSCT transplantation before.

• Subject with heart failure.

• Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.

• Pregnant or nursing women.

• Inability to understand or to follow study procedures.